Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Novel Brain-Computer Interface Enables ALS Patient to Speak and Sing

June 12, 2025

Researchers have developed an instantaneous brain-to-voice neuroprosthesis allowing a man with amyotrophic lateral sclerosis (ALS) to communicate using synthesized speech reproducing his own...

Synthetic Biology Boosts Monoclonal Antibody Production by Taming Cellular Evolution

June 12, 2025

Enduro Genetics reports a pioneering synthetic biology approach that counters cellular micro-evolution during monoclonal antibody (mAb) manufacturing. By harnessing biosensors and regulatory...

Bristol Myers Squibb Gains $350M Radiopharmaceutical Asset for Prostate Cancer

June 12, 2025

Bristol Myers Squibb’s RayzeBio unit licensed exclusive global rights to Philochem's OncoACP3, a prostate cancer-targeting diagnostic and radiopharmaceutical therapeutic candidate, via a $350...

Eli Lilly Invests Over $650M in Juvena for Muscle-Enhancing Therapies

June 12, 2025

Eli Lilly has partnered with Juvena Therapeutics in a deal featuring upfront payments and milestones exceeding $650 million to develop muscle health drugs. Juvena’s AI-driven platform maps...

Merck’s Cesrovimab Approved for Pediatric RSV Amid CDC Advisory Uncertainty

June 12, 2025

Merck received FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in newborns and...

BioNTech to Acquire CureVac in $1.25 Billion Stock Deal

June 12, 2025

BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating their positions in mRNA-based cancer immunotherapies and vaccines. This strategic move aims to...

SpliceBio Raises $135M Series B for Stargardt Gene Therapy

June 12, 2025

SpliceBio secured $135 million to advance its dual AAV gene therapy targeting Stargardt disease, a significant step for treating inherited retinal disorders. The financing bolsters clinical...

Genentech Layoffs Hit 143 Employees Amid Strategic Restructuring

June 12, 2025

Genentech announced workforce reductions of 143 roles at its South San Francisco headquarters as part of efforts to streamline operations. The layoffs follow prior cuts and organizational changes,...

BioNTech and CureVac Merger Boosts mRNA Cancer Therapy

June 12, 2025

BioNTech announced plans to acquire CureVac for $1.25 billion in an all-stock deal, consolidating two mRNA-focused biotechs. This acquisition enhances BioNTech's pipeline in cancer immunotherapy...

FDA Grants Sarepta Platform Technology Designation

June 12, 2025

The FDA has conferred a platform technology designation to Sarepta Therapeutics, aiming to streamline regulatory reviews for gene therapies the company may develop. This status is part of FDA...

Schrödinger Presents Early Phase 1 Data on MALT1 Inhibitor

June 12, 2025

Schrödinger reported preliminary safety and efficacy signals from an ongoing Phase 1 trial evaluating its MALT1 inhibitor. The findings reinforce the utility of the company's computational drug...

Nuvation Bio Secures FDA Approval for Lung Cancer Drug

June 12, 2025

Nuvation Bio received FDA approval for Ibtrozi (taletrectinib), targeting advanced ROS1-positive non-small cell lung cancer. Approval was based on robust response rates reported in multiple...

Bristol Myers Squibb Expands Radiopharmaceutical Portfolio

June 12, 2025

Bristol Myers Squibb, through its RayzeBio subsidiary, acquired global rights to Philochem AG’s OncoACP3, a radiopharmaceutical candidate for prostate cancer, with a $350 million upfront payment...

SpliceBio Closes $135 Million Series B to Advance Gene Therapy

June 12, 2025

SpliceBio secured $135 million in Series B funding to support clinical development of its lead gene therapy candidate, SB-007, for Stargardt disease. The dual AAV vector therapy aims to deliver...

Novel CRISPR-Cas13 RNA Editing Advances Therapeutics

June 12, 2025

Researchers have advanced RNA-targeting CRISPR-Cas13 technology to enable selective modification of desired RNA sequences in living cells. This next-generation gene therapy approach shows promise...

Innovative AI Accelerates Drug Discovery: Insilico Medicine Launch

June 12, 2025

Insilico Medicine launched Nach01, a multimodal foundation AI model on AWS Marketplace designed to accelerate generative chemistry for drug design. This large language model integrated with...

Breakthrough in Precision Gene Editing via Autophagy Induction

June 12, 2025

A Korean research team demonstrated that inducing autophagy significantly enhances homologous recombination efficiency during CRISPR-Cas9 genome editing. By shifting DNA repair pathways towards...

Robotic Innovations Enable Precision Agriculture Technologies

June 12, 2025

Cornell University researchers developed a soft robotic gripper capable of gently injecting sensors and genetic material into living plant leaves. This technology facilitates precise monitoring...

FDA Accelerates Gene Therapy Pathway with Sarepta Designation

June 12, 2025

The FDA has granted Sarepta Therapeutics a platform technology designation to streamline regulatory review for its gene therapy candidates, especially those targeting rare diseases. This status is...

Breakthroughs in Cancer Therapeutics and Diagnostics

June 12, 2025

Advances in cancer treatment continue with innovative clinical and preclinical studies. Saga Diagnostics launched a tumor-informed molecular residual disease test for early-stage breast cancer,...